METALL ZUG AG - WELCOME

Investor Presentation - March 11, 2024

Matthias Rey, CEO

Urs Scherrer, CFO

Bettine Killmer, Head of Corporate Communications & IR

Investor Presentation - March 11, 2024

1

METALL ZUG GROUP

WHAT WE PLANNED AND WHAT WE ACHIEVED 2023

Others

  • Maintain Gross Profit margin despite inflationary environment and price pressure on input side
  • Efficiency improvements in operations through further automation
  • R&D push: Further development of microscopy (analogue and digital), renewal of Octopus 910 and further development of Eyestar 900
  • Compensate pressure on material, freight and labor prices with higher sales prices
  • Further increase the share of recurring revenues (service, consumables), integration of Amity products in the Belimed Protect portfolio
  • Assess inorganic growth opportunities and further strategic alliances
  • Selection of winning project refActory
  • Start construction of SHL-Südtor
  • Conclude final agreement and define construction plan for project CreaTower I
  • Create sustainable positive single digit EBIT margin
  • Strengthen strategic focus of Gehrig Group

Investor Presentation - March 11, 2024

2

METALL ZUG GROUP

CONTENT

  1. Group Financial Report 2023
  2. Business Units
    • Infection Control
    • Joint Venture with Miele
    • Medical Devices
    • Others
    • Technologycluster & Infrastructure
  4. Sustainability @ Metall Zug
  5. Metall Zug Group - Outlook 2024
  6. Information for Investors

Investor Presentation - March 11, 2024

3

GROUP FINANCIAL REPORT FY 2023

METALL ZUG GROUP

OVERVIEW FY 2023

  • Group net sales of CHF 494.7 million (FY 22: CHF 645.9 million; CHF 487.0 excl. Schleuniger), organic sales increase 6.4%
    • Negative FX effect of CHF -16.3 million (-3.3%), acquisition- & divestment effect of CHF -7.1 million (-1.5%)
    • Infection Control: Organic sales growth of 3.6% mainly due to high order backlog at the end of 2022 and growth in Service and Consumables Business
    • Medical Devices: Significantly lower sales as a result of challenges in the US market, mainly due to destocking on distributors side resulting in low order entry
    • Belimed Life Science: Strong sales growth of 58.6% in 2023
    • Gehrig Group: Slightly higher sales mainly due to Service Business
  • Operating result (EBIT) of CHF 13.8 million (FY 22: CHF 135.9 million; CHF 25.5 million excl. Schleuniger)
    • Infection Control: Negative EBIT mainly due to negative FX effect and due to inflation-related wage increases and higher costs in R&D
    • Medical Devices: Sharp decrease in EBIT as a result of lower net sales and increased investments in R&D
    • Belimed Life Science: EBIT above 2022 and back in profit zone
    • Gehrig Group: Negative EBIT as a result of increased costs
  • Net result of CHF 26.7 million (FY 22: CHF 137.3 million)

Investor Presentation - March 11, 2024

5

GROUP FINANCIAL REPORT

INCOME STATEMENT

2022 excl.

2022

Schleuniger

CHF million

2023

in % (pro-forma)*

in %

(reported)

Comment

Net sales

494.7

100.0

487.0

100.0

645.9

Cost of Goods and Services sold

-343.1

-69.3

-324.1

-66.6

-419.2

Gross profit

151.7

30.7

162.9

33.4

226.7

Maketing and sales expenses

-56.7

-11.5

-56.9

-11.7

-73.7

Research and development expenses

-41.0

-8.3

-37.9

-7.8

-54.6

Administration expenses

-53.8

-10.9

-52.2

-10.7

-65.6

Other operating income

13.5

2.7

15.1

3.1

109.1

Other operating expenses

0.1

0.0

-5.5

-1.1

-6.0

2022: Includes deconsolidation impact of Schleuniger of CHF 89.7 million

2023: Includes CHF 2.1 million income from release of provision from disposal of UK pension plan

2022: Includes CHF -4.9 million expense related to UK pension plan

Operating result (EBIT)

13.8

2.8

25.5

5.2

135.9

Financial result

17.9

3.6

19.5

4.0

8.7

2023: Includes result from associated companies of CHF 17.0

million (2022: CHF 10.2 million)

Result before taxes

31.7

6.4

45.0

9.2

144.6

Taxes

-5.0

-1.0

-4.7

-1.0

-7.3

Net result

26.7

5.4

40.3

8.3

137.3

Thereof attributable to:

- Shareholders of Metall Zug AG

22.2

33.0

130.0

- Non-controlling interest holders

4.5

7.3

7.3

* To ensure comparability, the 2022 pro-forma figures are presented as if the merger between Schleuniger and Komax had already taken place on January 1, 2022.

Investor Presentation - March 11, 2024

6

GROUP FINANCIAL REPORT

ASSOCIATED COMPANIES

In CHF million

FY 2023

Komax

V-ZUG

Total

Pro rata net result

14.3

4.3

18.6

Adjustment to previous year's

actual result

-0.4

-1.2

-1.6

Total result

13.9

3.1

17.0

Book value (proportional equity)

107.7

141.3

249.0

Market value (share price as of December 31)

257.3

126.2

383.5

FY 2022

Komax

V-ZUG

Total

Pro rata net result

5.8

3.6

9.4

Adjustment to previous year's

actual result

n/a

0.5

0.5

Total result

5.8

4.1

9.9

Book value (proportional equity)

105.0

139.6

244.6

Market value (share price as of December 31)

330.5

177.2

507.7

Investor Presentation - March 11, 2024

7

GROUP FINANCIAL REPORT

NET SALES FY 23

by Business Unit

by region

Asia/Pacific/Others

15%

(17%)

Medical Devices

38%

(46%)

Others

24%

(17%)

Americas

35%

(41%)

Infection Control

38%

(37%)

Switzerland

17%

(12%)

Europe w/o

Switzerland

33%

(30%)

(Previous year's values in brackets - excluding Wire Processing)

Investor Presentation - March 11, 2024

8

GROUP FINANCIAL REPORT

NET SALES ANALYSIS

ORGANIC GROWTH

EXTERNAL

FX

GROUP

REPORTED

Net sales in CHF million

Investor Presentation - March 11, 2024

9

GROUP FINANCIAL REPORT

OPERATING RESULT (EBIT) ANALYSIS

OPERATIONAL (BUs)

EXTERNAL

GROUP

REPORTED

EBIT in CHF million

Investor Presentation - March 11, 2024

10

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Metall Zug AG published this content on 08 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 March 2024 06:30:09 UTC.